公开(公告)号：US20160068614A1

公开(公告)日：2016-03-10

申请号：US14843586

申请日：2015-09-02

Applicant: Alumend, LLC

Inventor： Ronald E. Utecht ,  Kaia L. Kloster ,  Millard M. Judy ,  Kevin J. Vaska ,  James L. Matthews

IPC: C08B37/08 ,  A61Q17/04 ,  A61K8/73

CPC classification number: C08B37/003 ,  A61B17/00 ,  A61B17/08 ,  A61K8/736 ,  A61K31/722 ,  A61K41/00 ,  A61K41/0042 ,  A61K41/0057 ,  A61K47/61 ,  A61K2800/57 ,  A61K2800/81 ,  A61K2800/94 ,  A61L24/08 ,  A61N5/062 ,  A61N2005/0602 ,  A61N2005/0663 ,  A61Q17/04 ,  A61Q19/00

Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

公开(公告)号：US20140350453A1

公开(公告)日：2014-11-27

申请号：US14293729

申请日：2014-06-02

Applicant: Alumend, LLC

Inventor： Ronald E. Utecht ,  Kaia L. Kloster ,  Millard M. Judy ,  Kevin J. Vaska ,  James L. Matthews

IPC: A61K41/00 ,  A61B17/08 ,  A61N5/06

CPC classification number: C08B37/003 ,  A61B17/00 ,  A61B17/08 ,  A61K8/736 ,  A61K31/722 ,  A61K41/00 ,  A61K41/0042 ,  A61K41/0057 ,  A61K47/61 ,  A61K2800/57 ,  A61K2800/81 ,  A61K2800/94 ,  A61L24/08 ,  A61N5/062 ,  A61N2005/0602 ,  A61N2005/0663 ,  A61Q17/04 ,  A61Q19/00

Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

Abstract translation: 萘二甲酰亚胺化合物用于组织结合和蛋白质交联应用。 当活化剂如400-500nm吸收范围的光激活时，萘酰亚胺化合物形成化学反应性物质，其将蛋白质交联，将结缔组织结合在一起，并将组织和其他生物材料结合在一起。 萘二甲酰亚胺标记的生物分子，例如萘二甲酰亚胺标记的壳聚糖，也能够粘合组织而不随后直接照射接触的组织区域。 萘二甲酰亚胺化合物可以用于组织或动脉修复，血管成形术后扩张的动脉壁的稳定化，将药剂束紧到组织表面以提供局部药物递送，以及将皮肤护理产品，防晒剂和化妆品化学粘合到皮肤上。

公开(公告)号：US20140187998A1

公开(公告)日：2014-07-03

申请号：US14126402

申请日：2012-06-14

Applicant: Richard Lang ,  David Copenhagen

Inventor： Richard Lang ,  David Copenhagen

IPC: A61N5/06 ,  A61B3/00

CPC classification number: A61N5/0613 ,  A61B3/0008 ,  A61F9/0079 ,  A61F2009/00863 ,  A61N5/0622 ,  A61N2005/0602 ,  A61N2005/0651 ,  A61N2005/0663

Abstract: A method of treating ROP, the method comprising providing a light source emitting light with a wavelength of about 490 nra, exposing an infant's eye to the light, and monitoring the vascularization in the infant's eye.

Abstract translation: 一种治疗ROP的方法，所述方法包括提供发射波长约490纳赫的光的光源，使婴儿的眼睛暴露于光，并监测婴儿的眼睛中的血管形成。

公开(公告)号：US08715327B1

公开(公告)日：2014-05-06

申请号：US12798966

申请日：2010-04-13

Applicant: Eric G. Lovett ,  Kip Ludwig

Inventor： Eric G. Lovett ,  Kip Ludwig

IPC: A61N5/06

CPC classification number: A61N5/0622 ,  A61N2005/0602 ,  A61N2005/0643 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662

Abstract: A system for stimulating a baroreflex of a patient that includes a first light source with a first emitter for emitting a first light, the first emitter at a first location proximate a target tissue having baroreceptor cells, and a second light source including a second emitter and for emitting a second light, the second emitter at a second location proximate the target tissue. The system also includes a control circuit coupled to the first and the second light sources, the control circuit configured to activate the first and the second light sources such that the first light traverses a first pathway to arrive at and penetrate the first portion of the target tissue and the second light-like traverses a second pathway to arrive at and penetrate the second portion of the target tissue, thereby stimulating the baroreceptor cells and activating a baroreflex of the patient.

Abstract translation: 一种用于刺激患者的压力反射的系统，其包括具有用于发射第一光的第一发射器的第一光源，在靠近具有压力感受器单元的靶组织的第一位置处的第一发射器和包括第二发射器的第二光源 用于在靠近目标组织的第二位置处发射第二个光，第二个发射器。 该系统还包括耦合到第一和第二光源的控制电路，该控制电路被配置为激活第一和第二光源，使得第一光穿过第一路径到达并穿透目标的第一部分 组织并且第二光线穿过第二通道以到达并穿透靶组织的第二部分，从而刺激压力感受器细胞并激活患者的压力反射。

公开(公告)号：US08546384B2

公开(公告)日：2013-10-01

申请号：US13547196

申请日：2012-07-12

Applicant: Ronald E. Utecht ,  Kaia L. Kloster ,  Millard M. Judy ,  Kevin J. Vaska ,  James L. Matthews

Inventor： Ronald E. Utecht ,  Kaia L. Kloster ,  Millard M. Judy ,  Kevin J. Vaska ,  James L. Matthews

IPC: A61K31/535

CPC classification number: C08B37/003 ,  A61B17/00 ,  A61B17/08 ,  A61K8/736 ,  A61K31/722 ,  A61K41/00 ,  A61K41/0042 ,  A61K41/0057 ,  A61K47/61 ,  A61K2800/57 ,  A61K2800/81 ,  A61K2800/94 ,  A61L24/08 ,  A61N5/062 ,  A61N2005/0602 ,  A61N2005/0663 ,  A61Q17/04 ,  A61Q19/00

Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

公开(公告)号：US20130178921A1

公开(公告)日：2013-07-11

申请号：US13783387

申请日：2013-03-03

Applicant: CHARLES BRIAN ROGERS

Inventor： CHARLES BRIAN ROGERS

IPC: A61N5/06

CPC classification number: A61N5/0624 ,  A61N5/06 ,  A61N2005/0602 ,  A61N2005/0652 ,  A61N2005/0661 ,  A61N2005/0662

Abstract: An application for a light source for killing blood pathogens. The light source includes multiple ultraviolet light emitting diodes and a visible-spectrum light emitting diode. A light mixer combines light from the ultraviolet light emitting diodes and the visible-spectrum light emitting diode and focuses a mixed light into a fiber optic for delivery to an intravenous needle. A controller adjusts an amount of current delivered to the ultraviolet light emitting diodes and visible-spectrum light emitting diode. A touch screen is interfaced to the controller for inputting commands and a display is interfaced to the controller for outputting information.

Abstract translation: 申请光源杀死血液病原体。 光源包括多个紫外发光二极管和可见光发光二极管。 光混合器组合来自紫外发光二极管和可见光发光二极管的光，并将混合光聚焦到光纤中以输送到静脉针。 控制器调节传递到紫外发光二极管和可见光发光二极管的电流量。 触摸屏与控制器接口用于输入命令，显示器与控制器接口输出信息。

公开(公告)号：US20130138033A1

公开(公告)日：2013-05-30

申请号：US13684382

申请日：2012-11-23

Applicant: Techlamed S.R.L. Societa Unipersonale

Inventor： Alessandro FRULLINI

IPC: A61N5/06

CPC classification number: A61N5/0613 ,  A61B18/20 ,  A61B18/22 ,  A61B18/24 ,  A61B18/245 ,  A61N5/06 ,  A61N2005/0602 ,  A61N2005/067

Abstract: The present invention relates to a method for treating varicose veins, which comprises: pre-treating a target vein segment with a pulsed laser radiation having a wavelength of from 1400 to 2300 nm, thereby causing a substantial diameter reduction of the target vein segment;delivering a sclerosing agent to the pre-treated target vein segment, thereby causing occlusion of the vein. The sclerosing agent is preferably a foam sclerosing agent. The above method in particularly effective also for larger veins, especially veins exceeding 10 mm of diameter, without causing major discomfort to the patients, and which has a very limited risk of side effects, such as those deriving from the injection of relatively large amounts of sclerosing agent or from damages to the vessel endothelium.

Abstract translation: 本发明涉及一种治疗静脉曲张的方法，包括：用波长为1400〜2300nm的脉冲激光辐射预处理目标静脉段，从而导致目标静脉段的实质直径减小; 向预处理的目标静脉段递送硬化剂，从而引起静脉闭塞。 硬化剂优选为泡沫硬化剂。 上述方法对于较大的静脉特别有效，特别是直径超过10mm的静脉，而不引起患者的重大不适，并且具有非常有限的副作用风险，例如来自注射相对大量 硬化剂或损伤血管内皮。

公开(公告)号：US20130123642A1

公开(公告)日：2013-05-16

申请号：US13583531

申请日：2011-03-07

Applicant: Takashi Yamaguchi ,  Shiho Hakomori ,  Koshi Tamamura ,  Tsunenori Arai ,  Arisa Ito ,  Jun Uchiyama

Inventor： Takashi Yamaguchi ,  Shiho Hakomori ,  Koshi Tamamura ,  Tsunenori Arai ,  Arisa Ito ,  Jun Uchiyama

IPC: A61B5/00

CPC classification number: A61B5/0071 ,  A61B5/0084 ,  A61B5/0402 ,  A61B5/4848 ,  A61B5/6852 ,  A61B5/6869 ,  A61B18/24 ,  A61B2018/00351 ,  A61N5/0601 ,  A61N5/062 ,  A61N2005/0602 ,  A61N2005/0626

Abstract: A photodynamic therapy apparatus as an estimating apparatus is an apparatus for irradiating a tissue having absorbed photo-sensitive pharmaceutical, the photo-sensitive pharmaceutical absorbing an excitation light and emitting fluorescence, with the excitation light emitted from a tip portion of a laser the catheter, including a connector, a light source, and a light detection unit. The laser the catheter is capable of being attached/detached to/from the connector. The light source outputs the excitation light to the laser the catheter via the connector. The light detection unit detects intensity or a spectrum of the fluorescence, the fluorescence being entered from the laser the catheter via the connector, to estimate whether the tissue has changed because of reaction between the excitation light emitted from the tip portion of the laser the catheter and the photo-sensitive pharmaceutical absorbed in the tissue.

Abstract translation: 作为估计装置的光动力治疗装置是一种用于从吸收了光敏药物的组织照射吸光激发光并发射荧光的光敏药物与从激光器的尖端部分发射的激发光的导管的装置， 包括连接器，光源和光检测单元。 激光器能够将导管与连接器连接/分离。 光源通过连接器将激发光输出到激光导管。 光检测单元检测荧光的强度或光谱，荧光通过连接器从激光导入导管，以估计组织是否因激光的尖端部分发射的激发光之间的反应而发生变化 和吸收在组织中的感光药物。

公开(公告)号：US20120283802A1

公开(公告)日：2012-11-08

申请号：US13554238

申请日：2012-07-20

Applicant: Chih-Ching LIN ,  Chyi-Ran LEE

Inventor： Chih-Ching LIN ,  Chyi-Ran LEE

IPC: A61N5/06

CPC classification number: A61N5/0613 ,  A61N2005/0602 ,  A61N2005/066

Abstract: The present invention provides a novel use of far-infrared radiation for improving patency of arteriovenous fistula, decreasing failure of arteriovenous fistula maturation and preventing and/or ameliorating peripheral artery diseases in a subject in need thereof. The radiation has an electromagnetic wave of about 1.5 to 100 μm wavelength, which performs on the subject skin surface for more than 10 minutes.

Abstract translation: 本发明提供远红外辐射的新用途，用于改善动静脉瘘的通畅，减少动静脉瘘成熟的失败，并预防和/或改善有需要的受试者的外周动脉疾病。 辐射具有约1.5至100μm波长的电磁波，其在主体皮肤表面上执行超过10分钟。

公开(公告)号：US20120004546A1

公开(公告)日：2012-01-05

申请号：US12976484

申请日：2010-12-22

Applicant: Wolfgang Neuberger ,  Endrick Groenhoff

Inventor： Wolfgang Neuberger ,  Endrick Groenhoff

IPC: A61B18/22 ,  A61N5/067 ,  A61N5/06

CPC classification number: A61N5/0603 ,  A61B8/12 ,  A61B8/4461 ,  A61N2005/0602 ,  A61N2005/0612 ,  A61N2005/063 ,  A61N2005/0644 ,  A61N2005/0659 ,  A61N2005/067

Abstract: A system and method for treating hemorrhoidal piles, addressing both cause and symptoms, by endoluminal/interstitial application of energy are disclosed. Inflamed dilated blood vessels (hemorrhoids/piles) are caused due to connective tissue disorder, relative increase in pressure in the superior hemorrhoidal artery and weakening of the vessels' valves. The dilated blood arteries in anal/rectal region are irradiated from inside the pile using (laser) energy for minimal pain/discomfort. The center of the pile is irradiated over a certain diameter, absorbing energy; is denatured causing volume reduction. Central vessels located in the same diameter are obliterated immediately relieving bleeding. In treatment, new connective tissue replaces the coagulated tissue. Closing inflowing arteries further shrinks piles in weeks to three months. Complications are highly diminished. A hand-piece and a fiber with a sharp distal tip are beneficial. Including an imaging system, (ultrasound imaging, optical coherence tomography) and an intelligent system to calculate necessary laser energy parameters help address each pile individually.

Abstract translation: 公开了一种通过腔内/间质施加能量治疗痔疮桩，解决原因和症状的系统和方法。 由于结缔组织紊乱引起扩张血管扩张的血管（痔疮/痔疮），上痔动脉压力相对增加，血管瓣膜减弱。 使用（激光）能量从肛门/直肠区域扩张的血管内照射桩，以减少疼痛/不适。 桩的中心照射一定直径，吸收能量; 变性导致体积减少。 位于相同直径的中央船只立即消除出血。 在治疗中，新的结缔组织代替凝固组织。 闭合流入的动脉在几周到三个月内进一步收缩桩。 并发症大大减少。 具有锋利的远端的手持件和纤维是有益的。 包括成像系统（超声成像，光学相干断层扫描）和智能系统来计算必要的激光能量参数有助于单独解决每个桩。